Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MBIO vs FBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FBIO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

FBIO Overall Winner 6-Pillar Tally: MBIO 1 – 4 FBIO (1 Tie) Matrix Metrics: MBIO 2 – 8 FBIO

As of Nov 16, 2026, Fortress Biotech, Inc. (FBIO) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas FBIO carries 50.4/100 (HOLD) at $1.71 (1.2x Forward P/E, -42.8% operating margin).

  • Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile FBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBIO vs FBIO
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap $3.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.66β · 86% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.4 · SMA20: $0.40 · SMA50: $0.44
FBIO NASDAQ Head-to-Head Winner
Fortress Biotech, Inc.
Pharmaceutical Preparations
$1.71
-9.04% 1D
Market Cap $62.7M
TTM Revenue $70M
Forward P/E 1.2x
Beta / 30D Vol 1.24β · 64% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 21.0 Fund 51.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.2%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $1.93 · SMA50: $2.12

6-Pillar Scorecard Institutional Category Breakdown (MBIO 1 – 4 FBIO)

Columns: Metric · MBIO · FBIO
1. Valuation Multiples FBIO
Forward P/E N/M 1.2x
Trailing P/E N/M 0.7x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale FBIO
Revenue Growth (YoY) +0.0% +8.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $70M
Market Cap $3.2M $62.7M
3. Profitability & Quality FBIO
Gross Margin N/A 66.1%
Operating Margin 0.0% -42.8%
Net Profit Margin 0.0% 143.1%
Return on Equity (ROE) -43.1% 102.5%
4. Balance Sheet & Cash Flow FBIO
Cash Generation (TTM) N/A $126M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.87 Book/Sh · -43.1% ROE $143M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MBIO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 48.3% (41st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBIO (2) vs FBIO (8)
Institutional Metric MBIO FBIO Criterion Row Edge
Market Capitalization
Scale
$3.2M $62.7M Larger Scale FBIO
Trailing P/E Ratio
Valuation
N/M 0.7x Lower Multiple FBIO
Forward P/E Ratio
Valuation
N/M 1.2x Lower Multiple FBIO
Revenue Growth (YoY)
Growth
+0.0% +8.7% Higher Growth FBIO
Operating Margin (TTM)
Profitability
0.0% -42.8% Higher Margin MBIO
Net Profit Margin
Profitability
0.0% 143.1% Higher Margin FBIO
Return on Equity (ROE)
Capital Efficiency
-43.1% 102.5% Higher ROE FBIO
52-Week Range Position
Momentum
4% ($0–$1) 0% ($2–$5) Stronger Trend MBIO
Beta / 30D Volatility
Risk Regime
0.66β · 86% Vol 1.24β · 64% Vol Lower Realized Risk FBIO
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 50.4 / 100 (HOLD) Higher Composite FBIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $70M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 66.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.87 Book/Sh · -43.1% ROE) $126M ($143M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBIO +13.42 pp
MBIO: +4.86% · FBIO: -8.56%
3M Horizon MBIO +10.49 pp
MBIO: -30.75% · FBIO: -41.24%
6M Horizon FBIO +2.94 pp
MBIO: -33.99% · FBIO: -31.05%
1Y Horizon FBIO +36.05 pp
MBIO: -67.38% · FBIO: -31.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs FBIO. Trailing 12-month operating profitability (MBIO 0.0% vs FBIO -42.8%) and valuation multiples (MBIO N/M vs FBIO 1.2x Forward P/E) are benchmarked directly in Pillar 4 below.

MBIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-43.1% · N/M
FBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$70M
Gross Margin66.1%
Op. Margin-42.8%
ROE / Fwd P/E102.5% · 1.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FBIO BREAKDOWN
88d in phase · OBV NEUTRAL
Current IV 48.3%
IV Percentile 41st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact FBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FBIO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and -42.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MBIO vs FBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Fortress Biotech, Inc. (FBIO) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas FBIO carries 50.4/100 (HOLD) at $1.71 (1.2x Forward P/E, -42.8% operating margin). Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile FBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FBIO leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FBIO at +8.7% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (66.1% gross margin, -42.8% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus $70M for FBIO. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FBIO.

FBIO screens cheaper on headline valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FBIO trades at 1.2x Forward P/E, 0.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus FBIO (102.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 86% Vol realized risk). By comparison, FBIO carries 48.3% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.24β · 64% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.